Global Friedreich's Ataxia Market Analysis 2023-2034: A Projected $3.39 Billion Opportunity Featuring Strategic Analysis of Reata Pharma, Pfizer, BioMarin Pharma, Retrotope, Voyager Therapeutics, and More
May 28, 2024 07:00 ET
|
Research and Markets
Dublin, May 28, 2024 (GLOBE NEWSWIRE) -- The "Global Friedreich's Ataxia Market" report has been added to ResearchAndMarkets.com's offering.The global Friedreich's ataxia market accounted for USD...
Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
May 16, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 16, 2024 (GLOBE NEWSWIRE) -- Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight...
Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense
July 19, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 19, 2023 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion,...
Anti-Aging Therapeutics Market Reach $ 2474.54 Million to 2031 with 17.5 % CAGR | Exclusive Report by InsightAce Analytic
March 08, 2023 10:31 ET
|
InsightAce Analytic Pvt. LTd.
Pune, March 08, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Anti-aging Therapeutics Market (Type of Molecule (Biologics and...
Global Ataxia Market Size To Grow USD 69,889.4 Million By 2030 | CAGR of 9.5%
November 28, 2022 13:30 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Global Ataxia Market Size to grow from USD 30,880.5 million in 2021 to USD 69,889.4 million by 2030, at a Compound Annual Growth Rate...
BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
September 15, 2022 07:00 ET
|
BioJiva, LLC
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger, Targeted TrialConsistent Benefit vs. Placebo in...
Multiple Sclerosis Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight
July 06, 2022 12:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, July 06, 2022 (GLOBE NEWSWIRE) -- Multiple Sclerosis Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight As per DelveInsight Multiple Sclerosis pipeline...
Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight
February 10, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry Age-Related Macular...
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
October 19, 2021 07:00 ET
|
Retrotope
Data Demonstrate RT011 Offers Dose-Dependent Protection Against Retinal Lipid Peroxidation (LPO) and Cell Damage, as well as Preservation of Visual Function Findings Provide Rationale for Advancement...
Seborrhoeic Dermatitis Pipeline: Pipeline Review, Novel and Emerging Therapeutic Drugs, Ongoing Clinical Trials Analysis, and Key Pharma Players| DelveInsight
October 14, 2021 20:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Seborrhoeic Dermatitis Pipeline: Pipeline Review, Novel and Emerging Therapeutic Drugs, Ongoing Clinical Trials Analysis, and Key Pharma Players|...